|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malvezzi M, Bertuccio P, Rosso T, Rota M
and Levi F: LaV ecchia C and Negri E: European cancer mortality
predictions for the year 2015: Does lung cancer have the highest
death rate in EU women? Ann Oncol. 26:779–786. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katanoda K, Hori M, Matsuda T, Shibata A,
Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An
updated report on the trends in cancer incidence and mortality in
Japan, 1958-2013. Jpn J Clin Oncol. 45:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barlesi F, Scherpereel A, Gorbunova V,
Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M,
et al: Maintenance bevacizumab-pemetrexed after first-line
cisplatin-pemetrexed-bevacizumab for advanced nonsquamous
nonsmall-cell lung cancer: Updated survival analysis of the AVAPERL
(MO22089) randomized phase III trial. Ann Oncol. 25:1044–1052.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cadranel J, Mauguen A, Faller M, Zalcman
G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel
C, et al: Impact of systematic EGFR and KRAS mutation evaluation on
progression-free survival and overall survival in patients with
advanced non-small-cell lung cancer treated by erlotinib in a
French prospective cohort (ERMETIC project-part 2). J Thorac Oncol.
7:1490–1502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshizawa A, Motoi N, Riely GJ, Sima CS,
Gerald WL, Kris MG, Park BJ, Rusch VW and Travis WD: Impact of
proposed IASLC/ATS/ERS classification of lung adenocarcinoma,
Prognostic subgroups and implications for further revision of
staging based on analysis of 514 stage I cases. Mod Pathol.
24:653–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amin MB, Tamboli P, Merchant SH, Ordóñez
NG, Ro J, Ayala AG and Ro JY: Micropapillary component in lung
adenocarcinoma, A distinctive histologic feature with possible
prognostic significance. Am J Surg Pathol. 26:358–364. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sánchez-Mora N, Presmanes MC, Monroy V,
Moreno N, Lara-Martínez JM, Aladro MH and Alvarez-Fernández E:
Micropapillary lung adenocarcinoma A distinctive histologic subtype
with prognostic significance. Histopathology. Hum Pathol.
39:324–330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Makimoto Y, Nabeshima K, Iwasaki H,
Miyoshi T, Enatsu S, Shiraishi T, Iwasaki A, Shirakusa T and
Kikuchi M: Micropapillary pattern, A distinct pathological marker
to subclassify tumours with a significantly poor prognosis within
small peripheral lung adenocarcinoma (</=20 mm) with mixed
bronchioloalveolar and invasive subtypes (Noguchi's type C
tumours). Histopathology. 46:677–684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyoshi T, Satoh Y, Okumura S, Nakagawa K,
Shirakusa T, Tsuchiya E and Ishikawa Y: Early-stage lung
adenocarcinomas with a micropapillary pattern, a distinct
pathologic marker for a significantly poor prognosis. Am J Surg
Pathol. 27:101–109. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Motoi N, Szoke J, Riely GJ, Seshan VE,
Kris MG, Rusch VW, Gerald WL and Travis WD: Lung adenocarcinoma,
Modification of the 2004 WHO mixed subtype to include the major
histologic subtype suggests correlations between papillary and
micropapillary adenocarcinoma subtypes, EGFR mutations and gene
expression analysis. Am J Surg Pathol. 32:810–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roh MS, Lee JI, Choi PJ and Hong YS:
Relationship between micropapillary component and micrometastasis
in the regional lymph nodes of patients with stage I lung
adenocarcinoma. Histopathology. 45:580–586. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Su Z, Dias-Santagata D, Duke M, Hutchinson
K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL,
Iafrate AJ and Pao W: A platform for rapid detection of multiple
oncogenic mutations with relevance to targeted therapy in
non-small-cell lung cancer. J Mol Diagn. 13:74–84. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Asano H, Toyooka S, Tokumo M, Ichimura K,
Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, et al:
Detection of EGFR gene mutation in lung cancer by mutant-enriched
polymerase chain reaction assay. Clin Cancer Res. 12:43–48. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tokumo M, Toyooka S, Ichihara S, Ohashi K,
Tsukuda K, Ichimura K, Tabata M, Kiura K, Aoe M, Sano Y, et al:
Double mutation and gene copy number of EGFR in gefitinib
refractory non-small-cell lung cancer. Lung Cancer. 53:117–121.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toyooka S, Matsuo K, Shigematsu H, Kosaka
T, Tokumo M, Yatabe Y, Ichihara S, Inukai M, Suehisa H, Soh J, et
al: The impact of sex and smoking status on the mutational spectrum
of epidermal growth factor receptor gene in non small cell lung
cancer. Clin Cancer Res. 13:5763–5768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Toyooka S, Tsukuda K, Ouchida M, Tanino M,
Inaki Y, Kobayashi K, Yano M, Soh J, Kobatake T, Shimizu N and
Shimizu K: Detection of codon 61 point mutations of the K-ras gene
in lung and colorectal cancers by enriched PCR. Oncol Rep.
10:1455–1459. 2003.PubMed/NCBI
|
|
20
|
Jokoji R, Yamasaki T, Minami S, Komuta K,
Sakamaki Y, Takeuchi K and Tsujimoto M: Combination of
morphological feature analysis and immunohistochemistry is useful
for screening of EML4-ALK-positive lung adenocarcinoma. J Clin
Pathol. 63:1066–1070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshida A, Tsuta K, Nakamura H, Kohno T,
Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K
and Tsuda H: Comprehensive histologic analysis of ALK-rearranged
lung carcinomas. Am J Surg Pathol. 35:1226–1234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takeuchi K, Choi YL, Soda M, Inamura K,
Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, et
al: Multiplex reverse transcription-PCR screening for EML4-ALK
fusion transcripts. Clin Cancer Res. 14:6618–6624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rodig SJ, Mino-Kenudson M, Dacic S, Yeap
BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, et
al: Unique clinicopathologic features characterize ALK-rearranged
lung adenocarcinoma in the western population. Clin Cancer Res.
15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paik JH, Choe G, Kim H, Choe JY, Lee HJ,
Lee CT, Lee JS, Jheon S and Chung JH: Screening of anaplastic
lymphoma kinase rearrangement by immunohistochemistry in non-small
cell lung cancer, Correlation with fluorescence in situ
hybridization. J Thorac Oncol. 6:466–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Inamura K, Takeuchi K, Togashi Y, Hatano
S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, et
al: EML4-ALK lung cancers are characterized by rare other
mutations, a TTF-1 cell lineage, an acinar histology and young
onset. Mod Pathol. 22:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mitsudomi T, Yatabe Y, Akita H, Genma A,
Soda M, Toyooka T, Nakagawa K, Nishio K and Hagiwara K: Guidance
for ALK gene testing in lung cancer patients. Biomarker Committee,
the Japan Lung Cancer Society. 2011.
|
|
28
|
De Oliveira Duarte Achcar R, Nikiforova MN
and Yousem SA: Micropapillary lung adenocarcinoma: EGFR, K-ras and
BRAF mutational profile. Am J Clin Pathol. 131:694–700. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ninomiya H, Hiramatsu M, Inamura K, Nomura
K, Okui M, Miyoshi T, Okumura S, Satoh Y, Nakagawa K, Nishio M, et
al: Correlation between morphology and EGFR mutations in lung
adenocarcinomas. Significance of the micropapillary pattern and the
hobnail cell type. Lung Cancer. 63:235–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al:
The relationship between epidermal growth factor receptor mutations
and clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
31
|
Mitsudomi T: Advances in target therapy
for lung cancer. Jpn J Clin Oncol. 40:101–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
